Cargando…

Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance

INTRODUCTION: This long-term post-marketing surveillance (SAPPHIRE) collected information on the safety and effectiveness of canagliflozin (approved dose 100 mg) prescribed to patients with type 2 diabetes mellitus (T2DM) in real-world practice in Japan. METHODS: Patients with T2DM who were prescrib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inagaki, Nobuya, Nangaku, Masaomi, Sakata, Yasushi, Sasaki, Kazuyo, Mori-Anai, Kazumi, Iwasaki, Tomohisa, Hamada, Koume
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799573/ https://www.ncbi.nlm.nih.gov/pubmed/34853985 http://dx.doi.org/10.1007/s12325-021-01984-4

Ejemplares similares

Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2022)

Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study in Japan
por: Wada, Takashi, et al.
Publicado: (2022)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
por: Wada, Takashi, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan
por: Tanaka, Tetsuhiro, et al.
Publicado: (2018)

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
por: Kato, Hideki, et al.
Publicado: (2018)

Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance
por: Ito, Shuichi, et al.
Publicado: (2018)

Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2015)

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study
por: Inagaki, Nobuya, et al.
Publicado: (2015)

Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan
por: Kadowaki, Takashi, et al.
Publicado: (2019)

Long‐term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2017)

Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with (111)In-labeled exendin-4
por: Hamamatsu, Keita, et al.
Publicado: (2019)

Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
por: Tanaka, Hiroyuki, et al.
Publicado: (2016)

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
por: Inagaki, Nobuya, et al.
Publicado: (2016)

New measures against chronic kidney diseases in Japan since 2018
por: Fukui, Akira, et al.
Publicado: (2019)

Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin
por: Polidori, David, et al.
Publicado: (2018)

Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
por: Sakata, Yukinori, et al.
Publicado: (2019)

Clinical Practice Changes After Post-Market Safety Reports on Desmopressin Orally Disintegrating Tablet in Japan: A Single-Center Retrospective Study
por: Yasuda, Takuma, et al.
Publicado: (2021)

Post-Marketing Surveillance of Fluvoxamine Maleate Used Long-Term in Patients with Social Anxiety Disorder in Japan
por: Asakura, Satoshi, et al.
Publicado: (2014)

SAPPHiRE and LHeC
por: Zimmermann, F
Publicado: (2012)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

Joining Alumina and Sapphire by Growing Aluminium Borate Whiskers In-Situ, and the Whiskers’ Orientation Relationship with the Sapphire Substrate
por: Li, Chun, et al.
Publicado: (2020)

Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan
por: Ito, Shuichi, et al.
Publicado: (2022)

Efficacy and safety of canagliflozin as add‐on therapy to a glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week, open‐label, phase IV study
por: Harashima, Shin‐ichi, et al.
Publicado: (2018)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Optogenetic activation of neocortical neurons in vivo with a sapphire-based micro-scale LED probe
por: McAlinden, Niall, et al.
Publicado: (2015)

Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Unmet needs in current clinical practice for insulinoma: Lessons from nationwide studies in Japan
por: Murakami, Takaaki, et al.
Publicado: (2021)

Real‐world outcomes of pembrolizumab monotherapy in non‐small cell lung cancer in Japan: A post‐marketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2022)

Crystal structure of canagliflozin hemihydrate
por: Liu, Kai-Hang, et al.
Publicado: (2016)

Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study
por: Kadowaki, Takashi, et al.
Publicado: (2017)

eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database
por: Itano, Seiji, et al.
Publicado: (2023)

Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients
por: Kadowaki, Takashi, et al.
Publicado: (2018)

Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
por: Haneda, Masakazu, et al.
Publicado: (2018)

Laser-Inscribed Stress-Induced Birefringence of Sapphire
por: Fan, Hua, et al.
Publicado: (2019)

Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_40ocd2pk9utthn8nkg8l6gvmv1